sx-682
syntrix
['sx-682 ']
live from #ash22! dr. david a. sallman of shares phase 1 results of the first in-class cxcr1/2 inhibitor sx-682 in patients with hypomethylating agent failure myelodysplastic syndromes. read more 
The official account of Moffitt Cancer Center. Our mission: to contribute to the prevention and cure of cancer. News and stories at https://t.co/XaP6iv4q19.